Jazz Pharmaceuticals PLC $JAZZ Shares Bought by Crossmark Global Holdings Inc.

Crossmark Global Holdings Inc. raised its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 68.4% in the 4th quarter, HoldingsChannel.com reports. The fund owned 6,187 shares of the specialty pharmaceutical company’s stock after buying an additional 2,513 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in Jazz Pharmaceuticals were worth $1,052,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also made changes to their positions in the company. Hilltop National Bank acquired a new stake in shares of Jazz Pharmaceuticals in the fourth quarter worth $36,000. Danske Bank A S acquired a new position in Jazz Pharmaceuticals during the third quarter valued at $40,000. Quent Capital LLC acquired a new position in Jazz Pharmaceuticals during the third quarter valued at $44,000. Geneos Wealth Management Inc. boosted its holdings in Jazz Pharmaceuticals by 57.6% in the first quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock valued at $47,000 after purchasing an additional 137 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd boosted its holdings in Jazz Pharmaceuticals by 1,383.3% in the third quarter. Caitong International Asset Management Co. Ltd now owns 356 shares of the specialty pharmaceutical company’s stock valued at $47,000 after purchasing an additional 332 shares during the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. Truist Financial raised Jazz Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, March 25th. Raymond James Financial restated an “outperform” rating and issued a $239.00 target price on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 6th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a report on Friday, March 27th. Piper Sandler lifted their price target on Jazz Pharmaceuticals from $219.00 to $232.00 and gave the company an “overweight” rating in a research report on Thursday, March 19th. Finally, Royal Bank Of Canada boosted their price target on Jazz Pharmaceuticals from $195.00 to $258.00 and gave the company an “outperform” rating in a report on Wednesday, May 6th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Jazz Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $230.56.

Jazz Pharmaceuticals Stock Up 2.0%

JAZZ opened at $232.33 on Thursday. Jazz Pharmaceuticals PLC has a fifty-two week low of $103.60 and a fifty-two week high of $235.00. The company has a debt-to-equity ratio of 0.95, a quick ratio of 1.85 and a current ratio of 2.04. The company has a fifty day moving average of $195.49 and a two-hundred day moving average of $175.49. The stock has a market capitalization of $14.58 billion, a price-to-earnings ratio of -11,610.69, a PEG ratio of 0.41 and a beta of 0.27.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings data on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share for the quarter. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. The business had revenue of $1.07 billion during the quarter. On average, research analysts expect that Jazz Pharmaceuticals PLC will post 20.75 earnings per share for the current year.

Insider Transactions at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, Director Norbert G. Riedel sold 3,415 shares of the firm’s stock in a transaction that occurred on Friday, February 27th. The stock was sold at an average price of $192.00, for a total value of $655,680.00. Following the sale, the director directly owned 7,024 shares of the company’s stock, valued at approximately $1,348,608. This trade represents a 32.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Bruce C. Cozadd sold 6,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $190.50, for a total value of $1,143,000.00. Following the completion of the sale, the director owned 384,682 shares of the company’s stock, valued at $73,281,921. This trade represents a 1.54% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 74,015 shares of company stock worth $14,180,486 over the last quarter. Company insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.